Novo Nordisk’s New Diabetes Combo Shows Potential To Best Lilly’s Mounjaro
Fierce Competition In Diabetes And Obesity Expected
New Phase II data shows combination of semaglutide plus a novel amylin analog outperforms semaglutide alone, and could surpass Lilly’s Mounjaro in helping weight loss in diabetes patients.
You may also be interested in...
With its GLP-1 analog already a stalwart in type 2 diabetes and weight loss, Novo Nordisk is investigating semaglutide as monotherapy and in combination regimens to treat non-alcoholic steatohepatitis.
Novo’s oral semaglutide generated 15.1% weight loss at 68 weeks in the Phase IIIa OASIS 1 study, but Lilly’s orforglipron provided up to 14.7% weight loss at 36 weeks in Phase II without reaching a plateau.
Mounjaro’s fourth quarter sales disappointed some analysts, but the launch remains off to a strong start. Donanemab now on track for full approval in Alzheimer’s, CEO Ricks pledges.